ESMO

Frontline Alecensa Extends Survival in Advanced ALK-Positive Lung Cancer

October 27th 2025, 5:00pm

Article

Alecensa cut the risk of death by 22% versus Xalkori, with median overall survival reaching 81.1 months versus 54.2 months in advanced ALK-positive lung cancer.

Hernexeos Effective in HER2-Mutated NSCLC

October 26th 2025, 2:00pm

Article

The Beamion LUNG-1 study showed that first-line Hernexeos had benefit for patients with HER2-mutated NSCLC.

Alternative Docetaxel Dosing Reduces Toxicity Risk in Prostate Cancer

October 22nd 2025, 4:00pm

Article

In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.

Verzenio Plus Endocrine Therapy Benefits Survival for Some With Breast Cancer

October 21st 2025, 8:00pm

Article

The addition of postsurgical Verzenio to endocrine therapy provided a benefit in HR–positive, HER2-negative breast cancer.

Buparlisib Plus Chemo Fails to Improve Head and Neck Cancer Survival

October 21st 2025, 3:27pm

Article

In PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma buparlisib and paclitaxel was not associated with a survival improvement.

VCN-01 with Standard Care Boosts Survival, Shows Safety in PDAC

October 20th 2025, 10:00pm

Article

VCN-01 plus standard chemotherapy and Abraxane proved safe and effective for patients with metastatic pancreatic cancer.

Camrelizumab Combo Extends Survival in Metastatic Cervical Cancer

October 20th 2025, 8:41pm

Article

Camrelizumab plus famitinib extended progression-free survival to 11.1 months versus 7.5 months with chemotherapy in recurrent or metastatic cervical cancer.

Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer

October 20th 2025, 8:15pm

Article

Alecensa achieved a 98.4% 4-year overall survival rate versus 92.4% with chemotherapy in resected ALK-positive early-stage lung cancer.

Trodelvy Plus Keytruda Upholds Quality of Life in TNBC

October 20th 2025, 7:29pm

Article

Trodelvy plus Keytruda may maintain quality of life and slow physical decline in metastatic triple-negative breast cancer.

Cancer Vaccine Plus Keytruda Slow Advanced Melanoma Progression

October 20th 2025, 5:37pm

Article

The cancer vaccine IO102-IO103 plus Keytruda was associated with a clinically relevant improvement in median progression-free survival.